{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:10Z","timestamp":1792511470188,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Trauma Acute Care Surg"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Trauma patients with hyperfibrinolysis and depletion of fibrinolytic inhibitors (DFIs) measured by thrombelastography (TEG) gain clot strength with TXA, but TEG results take nearly an hour. We aimed to develop an assay, plasmin TEG (P-TEG), to more expeditiously stratify risk for massive transfusion (MT), mortality, and hyperfibrinolysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>Trauma patients (N = 148) were assessed using TEG assays without exogenous additives (rapid\/native), with exogenous plasmin (P-TEG) or tissue plasminogen activator (tPA TEG). The plasmin dose used does not effect healthy-control clot lysis 30 minutes after maximum amplitude (LY30) but causes shortened reaction time (R time) relative to native TEG (P-TEG R time &lt; native TEG R time considered P-TEG negative). If P-TEG R time is greater than or equal to native TEG R time, the patient was considered P-TEG positive. Each assay's ability to predict MT, mortality, and (risk for) hyperfibrinolysis was determined. \u03c7<jats:sup>2<\/jats:sup> and Mann-Whitney <jats:italic toggle=\"yes\">U<\/jats:italic> tests were used to compare categorical and continuous variables, respectively. Results were reported as median \u00b1 interquartile range or n (%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Plasmin TEG provided results faster than all other assays (4.7 \u00b1 2.5\u20139.1 minutes), approximately 11-fold faster than rapid-TEG (rTEG) LY30 (54.2 \u00b1 51.1\u201358.1 minutes; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001). Plasmin TEG\u2013positive patients had greater than fourfold higher MT rate (30% vs. 7%; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.0015) with an area under the receiver operating characteristic curve of 0.686 (<jats:italic toggle=\"yes\">p<\/jats:italic> = 0.028), greater than fourfold higher 24-hour mortality (33.3% vs. 7.8%; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.0177), greater than twofold higher 30-day mortality (35% vs. 16.4%; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.0483), higher rates of DFI (55% vs. 18%; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001), and a trend toward elevated D-dimer (19.9 vs. 3.3 \u03bcg\/mL; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.14). Plasmin TEG was associated with hyperfibrinolysis on rTEG LY30 at the 7.6% threshold (<jats:italic toggle=\"yes\">p<\/jats:italic> = 0.04) but not the 3% threshold (<jats:italic toggle=\"yes\">p<\/jats:italic> = 0.40). Plasmin TEG performed best in relation to DFI, with a positive predictive value of 58% and negative predictive value of 81%. When combined with tPA TEG time to maximum amplitude, P-TEG outperformed rTEG LY30 for predicting MT (area under the receiver operating characteristic curve, 0.811 vs. 0.708).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Within 5 minutes, P-TEG can stratify patients at highest risk for MT, mortality, and risk for hyperfibrinolysis. In composite with tPA TEG time to maximum amplitude, P-TEG outperforms rTEG LY30 for predicting MT and does so four times faster (12.7 vs. 54.1 minutes). The rapid results of P-TEG may be useful for those who practice selective TXA administration to maximize TXA's time-dependent efficacy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>LEVEL OF EVIDENCE<\/jats:title>\n            <jats:p>Diagnostic test, level V.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ta.0000000000002941","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T18:02:24Z","timestamp":1599847344000},"page":"991-998","source":"Crossref","is-referenced-by-count":30,"title":["Plasmin thrombelastography rapidly identifies trauma patients at risk for massive transfusion, mortality, and hyperfibrinolysis: A diagnostic tool to resolve an international debate on tranexamic acid?"],"prefix":"10.1097","volume":"89","author":[{"given":"Christopher D.","family":"Barrett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter B.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Vigneshwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Dhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sauaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest E.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Yaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"issue":"6","key":"bib1-20230825","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/TA.0000000000000341","article-title":"Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy","volume":"77","year":"2014","journal-title":"J Trauma Acute Care Surg"},{"issue":"4","key":"bib2-20230825","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jamcollsurg.2016.01.006","article-title":"Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: a multicenter evaluation of 2,540 severely injured patients","volume":"222","year":"2016","journal-title":"J Am Coll Surg"},{"issue":"3","key":"bib3-20230825","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.surg.2015.05.004","article-title":"Prevalence and impact of admission hyperfibrinolysis in severely injured pediatric trauma patients","volume":"158","year":"2015","journal-title":"Surgery"},{"issue":"1","key":"bib4-20230825","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/TA.0b013e3182598c70","article-title":"Criteria for empiric treatment of hyperfibrinolysis after trauma","volume":"73","year":"2012","journal-title":"J Trauma Acute Care Surg"},{"issue":"9734","key":"bib5-20230825","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial","volume":"376","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"bib6-20230825","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/TA.0000000000000242","article-title":"Do all trauma patients benefit from tranexamic acid?","volume":"76","year":"2014","journal-title":"J Trauma Acute Care Surg"},{"key":"bib7-20230825","first-page":"874920","article-title":"CRASH-2 study of tranexamic acid to treat bleeding in trauma patients: a controversy fueled by science and social media","volume":"2015","year":"2015","journal-title":"J Blood Transfus"},{"issue":"2","key":"bib8-20230825","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/archsurg.2011.287","article-title":"Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) study","volume":"147","year":"2012","journal-title":"Arch Surg"},{"issue":"1","key":"bib9-20230825","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jamcollsurg.2019.03.015","article-title":"Does tranexamic acid improve clot strength in severely injured patients who have elevated fibrin degradation products and low fibrinolytic activity, measured by thrombelastography?","volume":"229","year":"2019","journal-title":"J Am Coll Surg"},{"key":"bib10-20230825","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jss.2017.04.028","article-title":"Tranexamic acid is associated with increased mortality in patients with physiological fibrinolysis","volume":"220","year":"2017","journal-title":"J Surg Res"},{"issue":"1","key":"bib11-20230825","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/TA.0000000000002061","article-title":"Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism","volume":"86","year":"2019","journal-title":"J Trauma Acute Care Surg"},{"issue":"6 Suppl 1","key":"bib12-20230825","first-page":"S65","article-title":"Postinjury fibrinolysis shutdown: rationale for selective tranexamic acid","volume":"78","year":"2015","journal-title":"J Trauma Acute Care Surg"},{"issue":"10241","key":"bib13-20230825","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)30848-5","article-title":"Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial","volume":"395","year":"2020","journal-title":"Lancet"},{"issue":"Suppl 2","key":"bib14-20230825","first-page":"S110","article-title":"Rationale for the selective administration of tranexamic acid to inhibit fibrinolysis in the severely injured patient","volume":"56","year":"2016","journal-title":"Transfusion"},{"issue":"10116","key":"bib15-20230825","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(17)32455-8","article-title":"Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients","volume":"391","year":"2018","journal-title":"Lancet"},{"issue":"9771","key":"bib16-20230825","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(11)60278-X","article-title":"The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial","volume":"377","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"bib17-20230825","first-page":"407","article-title":"Rapid thrombelastography delivers real-time results that predict transfusion within 1 hour of admission","volume":"71","year":"2011","journal-title":"J Trauma"},{"issue":"1","key":"bib18-20230825","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jamcollsurg.2017.02.018","article-title":"Viscoelastic tissue plasminogen activator challenge predicts massive transfusion in 15 minutes","volume":"225","year":"2017","journal-title":"J Am Coll Surg"},{"key":"bib19-20230825","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.surg.2019.05.011","article-title":"Clot activators do not expedite the time to predict massive transfusion in trauma patients analyzed with tissue plasminogen activator thrombelastography","volume":"166","year":"2019","journal-title":"Surgery"},{"issue":"1","key":"bib20-20230825","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood.V73.1.185.185","article-title":"Activation\/inactivation of human factor V by plasmin","volume":"73","year":"1989","journal-title":"Blood"},{"key":"bib21-20230825","first-page":"24","article-title":"Natural inhibitors of fibrinolysis","volume":"14","year":"1980","journal-title":"J Clin Pathol Suppl"},{"issue":"6","key":"bib22-20230825","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/SHK.0000000000000161","article-title":"Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients","volume":"41","year":"2014","journal-title":"Shock"},{"issue":"1","key":"bib23-20230825","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/TA.0000000000000885","article-title":"Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients","volume":"80","year":"2016","journal-title":"J Trauma Acute Care Surg"},{"issue":"6","key":"bib24-20230825","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/SLA.0000000000001608","article-title":"Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays","volume":"263","year":"2016","journal-title":"Ann Surg"},{"issue":"6","key":"bib25-20230825","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/TA.0b013e3182aa9c9f","article-title":"Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy","volume":"75","year":"2013","journal-title":"J Trauma Acute Care Surg"},{"issue":"2","key":"bib26-20230825","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/TA.0b013e31825c1234","article-title":"Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration","volume":"73","year":"2012","journal-title":"J Trauma Acute Care Surg"},{"issue":"1","key":"bib27-20230825","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/TA.0000000000001270","article-title":"Rapid thrombelastography thresholds for goal-directed resuscitation of patients at risk for massive transfusion","volume":"82","year":"2017","journal-title":"J Trauma Acute Care Surg"},{"issue":"6","key":"bib29-20230825","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/SLA.0000000000002733","article-title":"The S100A10 pathway mediates an occult hyperfibrinolytic subtype in trauma patients","volume":"269","year":"2019","journal-title":"Ann Surg"},{"issue":"Suppl 1","key":"bib30-20230825","first-page":"S195","article-title":"Tranexamic acid in trauma: how should we use it?","volume":"13","year":"2015","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Trauma and Acute Care Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TA.0000000000002941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T10:21:07Z","timestamp":1692958867000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TA.0000000000002941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ta.0000000000002941","relation":{},"ISSN":["2163-0763","2163-0755"],"issn-type":[{"value":"2163-0763","type":"electronic"},{"value":"2163-0755","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,14]]}}}